Steward Partners Investment Advisory LLC Lowers Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Steward Partners Investment Advisory LLC reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 55.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,342 shares of the medical equipment provider's stock after selling 10,457 shares during the quarter. Steward Partners Investment Advisory LLC's holdings in Zimmer Biomet were worth $881,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. CKW Financial Group increased its stake in Zimmer Biomet by 11.7% during the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock worth $101,000 after acquiring an additional 100 shares during the period. FWG Holdings LLC raised its holdings in Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider's stock valued at $372,000 after acquiring an additional 101 shares in the last quarter. Romano Brothers AND Company raised its holdings in Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock valued at $1,000,000 after acquiring an additional 102 shares in the last quarter. Dakota Wealth Management raised its holdings in Zimmer Biomet by 1.3% in the 4th quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock valued at $1,016,000 after acquiring an additional 122 shares in the last quarter. Finally, Empirical Finance LLC raised its holdings in Zimmer Biomet by 2.2% in the 3rd quarter. Empirical Finance LLC now owns 7,180 shares of the medical equipment provider's stock valued at $775,000 after acquiring an additional 156 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Remove Ads

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.95% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Royal Bank of Canada dropped their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Truist Financial reissued a "hold" rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Trading Up 3.5 %

Shares of NYSE ZBH traded up $3.60 during trading on Thursday, reaching $107.63. The company had a trading volume of 2,062,515 shares, compared to its average volume of 1,921,875. The company's fifty day moving average price is $105.72 and its 200-day moving average price is $107.06. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The stock has a market cap of $21.43 billion, a P/E ratio of 24.19, a PEG ratio of 1.95 and a beta of 1.04. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the firm posted $2.20 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.